Abstract:e13651 Background: With the general application of EGFR TKI in treatment for NSCLC, more and more adherent and acquired resistance to such agents happens. To further improve efficacy of this kind of agents, a better understanding of the mechanism of resistance is necessary. Methods: Gefitinib-resistant PC9/G cell lines was induced by exposure of PC9 cell lines to MNNG and gefitinib and maintained in the mediua containing 0.05 umol/L of gefitinib. The inhibitory effects of gefitinib and/or LY294002 and PD98059 on cellular proliferation were tested by MTT assay. Cell cycle and apoptosis were analyzed by flow cytometry. Western Blot was used to detect expression of EGFR, phospho-EGFR, Akt and phospho-Akt. The different profiles of gene expression between PC9 and PC9/G cells were obtained by DNA microarray. β1 integrin was knocked down by transiently transfected siRNA. A scrambled sequence was used as control. The sensitivity to gefitinib of transfected cells was determined by MTT assay. Sequencing products were amplified by nested PCR. Apoptosis of transfected cells was assayed by TUNEL methods. Results: Resistant index of PC9/G to gefitinib was about 140 to 241 fold compared with PC9.Overexpression of β1 integrin was observed in PC9/G. Depletion of β1 integrin with shRNA results in inhibition of proliferation and promotion of apoptosis of PC9/G. Phosphorylation of Akt was less inhibited by gefitinib in PC9/G than in PC9. The restoration of sensitivity of PC9/G to gefitinib by LY294002, PI3-K inhibitor, and the diminished level of phospho-Akt induced by knock down of β1 integrin with RNAi. Conclusions: These findings suggest that β1 integrin signaling through PI3-K may be an important mechanism of resistance to EGFR TKIs and β1 integrin may be a therapeutic target for treatment of NSCLC unresponsive to EGFR inhibitors. No significant financial relationships to disclose.

Construction of A High-Egfr Expression Cell Line and Its Biological Properties Comparing with A431 Cell

Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics.

Construction and Identification of Lentiviral Vector-mediated RNA Interference of Epidermal Growth Factor Receptor

Effect of epidermal growth factor (EGF) on the biological characteristics of a cell line expressing EGF receptor on its membrane

Expression of Intracellular Domain of Epidermal Growth Factor Receptor and Generation of Its Monoclonal Antibody

Analysis of the in vitro function and internalization ability of a humanized EGFR antibody AE01 expressed by Chinese hamster ovary cells

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Transient Transfection of Short Hairpin RNA Targeting Epidermal Growth Factor Receptor into Lung Adenocarcinoma A549 Cell Line and Its Effect on Cell Growth and Sensitivity to Cytotoxic Drugs

Inhibitory Effect of Resveratrol on EGFR-mediated Tumor

Prokaryotic expression and refolding of EGFR extracellular domain and generation of phage display human scFv against EGFR.

Construction of Small Interfering RNA Expression Vector Targeting EGFR Gene and Its Biologic Effects

Construction of Recombinant FGFR1 Containing Full-Length Gene and Its Potential Application

Construction of the tissue engineering seed cells (HaCaT-epidermal growth factor) and analysis of its biological characteristics

The Construction of Anti-EGFR Single Chain Variable Fragment Fused with Gelonin Toxin Prokaryotic Expressing Plasmid and the Study of Its Anti-tumor Effects

Selection and characterization of an internalizing epidermal-growth-factor-receptor antibody.

Discovery of EGFR-Targeted Environment-Sensitive fluorescent probes for cell imaging and efficient tumor detection

Inhibitory effects of RNA interference and Erlotinib by blocking epidermal growth factor receptor pathway on the proliferation of A549 cells

Potential Role of Short Hairpin RNA Targeting Epidermal Growth Factor Receptor in Growth and Sensitivity to Drugs of Human Lung Adenocarcinoma Cells.

Construction of the Tissue Engineering Seed Cells (Hacat-Egf) and Analysis of Its Biological Characteristics

Quantification of Epidermal Growth Factor Receptor Expression Level and Binding Kinetics on Cell Surfaces by Surface Plasmon Resonance Imaging

Preclinical and Clinical Evaluations of ABX-EGF, a Fully Human Anti-Epidermal Growth Factor Receptor Antibody.